MedPath

12-Month Stability of Diurnal IOP Control on Cosopt

Phase 4
Completed
Conditions
Glaucoma
Interventions
Registration Number
NCT00379834
Lead Sponsor
West Virginia University
Brief Summary

To determine the stability of diurnal intraocular pressure in eyes with glaucoma treated with Cosopt

Detailed Description

Glaucoma is a potentially-blinding but treatable eye disease. A major risk factor for glaucoma is elevated intraocular pressure (IOP). IOP is a dynamic variable (like blood pressure)-it changes over time. The more it changes, the more likely patients are to get worse. Glaucoma is treated by lowering IOP. Cosopt is a medication that lowers IOP. Little is known about how well Cosopt reduces IOP fluctuations. In this study, we plan to measure the IOP in both eyes of 10 glaucoma patients treated with Cosopt, every 2 hours from 8am to 8pm, on five separate days over a one-year period. Untreated baseline IOP will be measured on a similar long day before beginning treatment with Cosopt. This methodology will allow us to compare IOP fluctuations with and without Cosopt, and also to learn about long-term control of IOP fluctuations in eyes treated with Cosopt.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • bilateral open-angle glaucoma
Exclusion Criteria
  • contraindications to Cosopt
  • pathology affecting tonometry

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
CosoptCosoptCosopt twice daily in both eyes
Primary Outcome Measures
NameTimeMethod
Diurnal Intraocular Pressure Control12 months

Change from baseline in mean diurnal IOP (measured every two hours from 8AM to 8PM) averaged across on-treatment study visits (week 1, months 1, 6, 12)

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath